BH3-only proteins target BCL-xL/MCL-1, not BAX/BAK, to initiate apoptosis.


Journal

Cell research
ISSN: 1748-7838
Titre abrégé: Cell Res
Pays: England
ID NLM: 9425763

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 30 01 2019
accepted: 30 08 2019
pubmed: 26 9 2019
medline: 9 9 2020
entrez: 26 9 2019
Statut: ppublish

Résumé

It has been widely accepted that mitochondria-dependent apoptosis initiates when select BH3-only proteins (BID, BIM, etc.) directly engage and allosterically activate effector proteins BAX/BAK. Here, through reconstitution of cells lacking all eight pro-apoptotic BH3-only proteins, we demonstrate that all BH3-only proteins primarily target the anti-apoptotic BCL-2 proteins BCL-xL/MCL-1, whose simultaneous suppression enables membrane-mediated spontaneous activation of BAX/BAK. BH3-only proteins' apoptotic activities correlate with affinities for BCL-xL/MCL-1 instead of abilities to directly activate BAX/BAK. Further, BID and BIM do not distinguish BAX from BAK or accelerate BAX/BAK activation following inactivation of BCL-xL/MCL-1. Remarkably, death ligand-induced apoptosis in cells lacking BH3-only proteins and MCL-1 is fully restored by BID mutants capable of neutralizing BCL-xL, but not direct activation of BAX/BAK. Taken together, our findings provide a "Membrane-mediated Permissive" model, in which the BH3-only proteins only indirectly activate BAX/BAK by neutralizing the anti-apoptotic BCL-2 proteins, and thus allowing BAX/BAK to undergo unimpeded, spontaneous activation in the mitochondrial outer membrane milieu, leading to apoptosis initiation.

Identifiants

pubmed: 31551537
doi: 10.1038/s41422-019-0231-y
pii: 10.1038/s41422-019-0231-y
pmc: PMC6888900
doi:

Substances chimiques

BAK1 protein, human 0
BCL2 protein, human 0
BCL2L1 protein, human 0
BH3 Interacting Domain Death Agonist Protein 0
BID protein, human 0
Bcl-2-Like Protein 11 0
MCL1 protein, human 0
Myeloid Cell Leukemia Sequence 1 Protein 0
Proto-Oncogene Proteins c-bcl-2 0
bcl-2 Homologous Antagonist-Killer Protein 0
bcl-X Protein 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

942-952

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM118437
Pays : United States
Organisme : NCI NIH HHS
ID : R03 CA205496
Pays : United States
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS)
ID : 5R01GM118437
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : 5R03CA205496
Organisme : NIGMS NIH HHS
ID : R01 GM076237
Pays : United States
Organisme : NCRR NIH HHS
ID : P20 RR018759
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Adams, J. M. & Cory, S. The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Differ. 25, 27–36 (2018).
pubmed: 31745318
Youle, R. J. & Strasser, A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9, 47–59 (2008).
pubmed: 18097445 pmcid: 18097445
Chipuk, J. E. & Green, D. R. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol. 18, 157–164 (2008).
pubmed: 18314333 pmcid: 18314333
Jiang, X. & Wang, X. Cytochrome C-mediated apoptosis. Annu. Rev. Biochem. 73, 87–106 (2004).
pubmed: 15189137
Letai, A. et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2, 183–192 (2002).
pubmed: 12242151
Kim, H. et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat. Cell Biol. 8, 1348–1358 (2006).
pubmed: 17115033
Czabotar, P. E. et al. Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. Cell 152, 519–531 (2013).
pubmed: 23374347
Kim, H. et al. Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol. Cell 36, 487–499 (2009).
pubmed: 19917256 pmcid: 3163439
Gavathiotis, E. et al. BAX activation is initiated at a novel interaction site. Nature 455, 1076–1081 (2008).
pubmed: 18948948 pmcid: 2597110
Lovell, J. F. et al. Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. Cell 135, 1074–1084 (2008).
pubmed: 19062087 pmcid: 19062087
Czabotar, P. E., Lessene, G., Strasser, A. & Adams, J. M. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat. Rev. Mol. Cell Biol. 15, 49–63 (2014).
pubmed: 24355989
Kuwana, T. et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol. Cell 17, 525–535 (2005).
pubmed: 15721256
Kuwana, T. et al. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 111, 331–342 (2002).
pubmed: 12419244
Sarosiek, K. A. et al. BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. Mol. Cell 51, 751–765 (2013).
pubmed: 24074954 pmcid: 4164233
Du, H. et al. BH3 domains other than Bim and Bid can directly activate Bax/Bak. J. Biol. Chem. 286, 491–501 (2011).
pubmed: 21041309 pmcid: 21041309
Hockings, C. et al. Bid chimeras indicate that most BH3-only proteins can directly activate Bak and Bax, and show no preference for Bak versus Bax. Cell Death Dis. 6, e1735 (2015).
pubmed: 25906158 pmcid: 4650538
Chen, H. C. et al. An interconnected hierarchical model of cell death regulation by the BCL-2 family. Nat. Cell Biol. 17, 1270–1281 (2015).
pubmed: 26344567 pmcid: 4589531
Luna-Vargas, M. P. A. & Chipuk, J. E. Physiological and pharmacological control of BAK, BAX, and beyond. Trends Cell Biol. 26, 906–917 (2016).
pubmed: 27498846 pmcid: 5118054
Dai, H. et al. Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization. J. Cell Biol. 194, 39–48 (2011).
pubmed: 21727192 pmcid: 3135403
Willis, S. N. et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 19, 1294–1305 (2005).
pubmed: 15901672 pmcid: 1142553
Willis, S. N. et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315, 856–859 (2007).
pubmed: 17289999
Edlich, F. et al. Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol. Cell 145, 104–116 (2011).
pubmed: 21458670 pmcid: 3070914
O’Neill, K. L., Huang, K., Zhang, J., Chen, Y. & Luo, X. Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane. Genes Dev. 30, 973–988 (2016).
pubmed: 27056669 pmcid: 27056669
Lopez, H. et al. Perturbation of the Bcl-2 network and an induced Noxa/Bcl-xL interaction trigger mitochondrial dysfunction after DNA damage. J. Biol. Chem. 285, 15016–15026 (2010).
pubmed: 20223826 pmcid: 2865346
Zhang, L. et al. Selective involvement of BH3-only proteins and differential targets of Noxa in diverse apoptotic pathways. Cell Death Differ. 18, 864–873 (2011).
pubmed: 21113147
Pang, X. et al. The carboxyl-terminal tail of Noxa protein regulates the stability of Noxa and Mcl-1. J. Biol. Chem. 289, 17802–17811 (2014).
pubmed: 24811167 pmcid: 4067213
Chen, L. et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell 17, 393–403 (2005).
pubmed: 15694340
Li, H., Zhu, H., Xu, C. J. & Yuan, J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94, 491–501 (1998).
pubmed: 9727492 pmcid: 9727492
Luo, X., Budihardjo, I., Zou, H., Slaughter, C. & Wang, X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94, 481–490 (1998).
pubmed: 9727491 pmcid: 9727491
Kotschy, A. et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 538, 477–482 (2016).
pubmed: 27760111 pmcid: 27760111
Huang, K. et al. Cleavage by caspase 8 and mitochondrial membrane association activate the BH3-only protein bid during TRAIL-induced apoptosis. J. Biol. Chem. 291, 11843–11851 (2016).
pubmed: 27053107
Moldoveanu, T., Follis, A. V., Kriwacki, R. W. & Green, D. R. Many players in BCL-2 family affairs. Trends Biochem. Sci. 39, 101–111 (2014).
pubmed: 24503222 pmcid: 4005919
Wang, K., Yin, X. M., Chao, D. T., Milliman, C. L. & Korsmeyer, S. J. BID: a novel BH3 domain-only death agonist. Genes Dev. 10, 2859–2869 (1996).
pubmed: 8918887
Llambi, F. et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol. cell 44, 517–531 (2011).
pubmed: 22036586 pmcid: 3221787
Walensky, L. D. & Gavathiotis, E. BAX unleashed: the biochemical transformation of an inactive cytosolic monomer into a toxic mitochondrial pore. Trends Biochem. Sci. 36, 642–652 (2011).
pubmed: 21978892 pmcid: 3454508
Moldoveanu, T. et al. BID-induced structural changes in BAK promote apoptosis. Nat. Struct. Mol. Biol. 20, 589–597 (2013).
pubmed: 23604079 pmcid: 3683554
Borner, C. & Andrews, D. W. The apoptotic pore on mitochondria: are we breaking through or still stuck? Cell Death Differ. 21, 187–191 (2014).
pubmed: 24413197 pmcid: 3890960
Hsu, Y. T. & Youle, R. J. Bax in murine thymus is a soluble monomeric protein that displays differential detergent-induced conformations. J. Biol. Chem. 273, 10777–10783 (1998).
pubmed: 9553144
Suzuki, M., Youle, R. J. & Tjandra, N. Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 103, 645–654 (2000).
pubmed: 11106734
Fletcher, J. I. et al. Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. Proc. Natl Acad. Sci. USA 105, 18081–18087 (2008).
pubmed: 18981409
Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677–681 (2005).
pubmed: 15902208 pmcid: 15902208
Greaves, G. et al. BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL. Cell Death Differ. 26, 1037–1047 (2019).
pubmed: 30185825
Pitti, R. M., Marsters, S. A., Ruppert. S., Donahue, C. J., Moore, A., Ashkenazi, A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271, 12687–12690 (2019).
pubmed: 8663110
George, N. M., Evans, J. J. & Luo, X. A three-helix homo-oligomerization domain containing BH3 and BH1 is responsible for the apoptotic activity of Bax. Genes Dev. 21, 1937–1948 (2007).
pubmed: 17671092 pmcid: 1935031
Pang, X. et al. Active Bax and Bak are functional holins. Genes Dev. 25, 2278–2290 (2011).
pubmed: 22006182 pmcid: 3219232

Auteurs

Kai Huang (K)

Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68198-7696, USA.
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, 68198-7696, USA.

Katelyn L O'Neill (KL)

Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68198-7696, USA.

Jian Li (J)

Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68198-7696, USA.
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, 68198-7696, USA.

Wei Zhou (W)

Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68198-7696, USA.
Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China.

Na Han (N)

Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68198-7696, USA.
Department of Oncology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, 450014, Henan, China.

Xiaming Pang (X)

Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68198-7696, USA.

Wei Wu (W)

Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68198-7696, USA.
Department of Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China.

Lucas Struble (L)

Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68198-7696, USA.

Gloria Borgstahl (G)

Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68198-7696, USA.

Zhaorui Liu (Z)

Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68198-7696, USA.
School of Medicine, Shandong University, Jinan, 250012, Shandong, China.

Liqiang Zhang (L)

Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68198-7696, USA.

Xu Luo (X)

Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68198-7696, USA. xuluo@unmc.edu.
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, 68198-7696, USA. xuluo@unmc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH